Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

US FDA Appoints Another Orphan Products Development Office Head Amid Growth Expectations

Executive Summary

Janet Maynard will become acting Office of Orphan Products Development director at the end of October, the fourth head of the office in the last 10 months; staff is expected to grow and may begin to provide development advice.

You may also be interested in...



FDA’s New Orphan Products Director Brings Industry, Legal, Academic, Regulatory Background

Sandra Retzky worked at AstraZeneca and in Delaware's Medicaid fraud unit before joining the US FDA in 2016.

US FDA Seeking New Orphan Products Office Director Amid Internal Moves

OOPD’s deputy director has been named the acting head of the office responsible for orphan and rare pediatric disease designations.

US FDA Expands Patient Input To New Area: Orphan Grant Applications

Patient experience will be incorporated into agency orphan grant reviews, and outside rare disease experts will help make decisions.

Related Content

Topics

UsernamePublicRestriction

Register

PS124067

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel